KEAP1 and breast cancer: The outcomes implied that the Keap1-Nrf2 PPI inhibitors have possible antioxidant activity by activating Nrf2 pathways and inhibiting E2-induced gene and protein expression, serving as potential agents for reducing the development of BC [40].